Recombinant Human TFF2 protein

• Cat.No.: TFF2-30657TH
• Product Overview: Recombinant Human TFF2 protein was expressed in Escherichia coli.

Specification

• Description: Trefoil factor 2 encoded by the TFF2 gene in humans, belongs to the trefoil factor family that consists of three members named TFF1, TFF2 and TFF3. They are characterized by having at least one copy of the trefoil motif, a 40-amino acid domain that contains three conserved disulfides. The TFFs are stable secretory proteins expressed highly in the gastrointestinal tract (gastric mucosa). TFF2 can inhibit gastrointestinal motility and gastric acid secretion. Additionally, it functions as a structural component of gastric mucus, possibly by stabilizing glycoproteins in the mucus gel through interactions with carbohydrate side chains.
• Source: E.coli
• Species: Human
• Form: Lyophilized from a 0.2μm filtered concentrated solution in 20 mM PB, pH 7.4, 130 mM NaCl.
• Bio-activity: Fully biologically active when compared to standard. The ED50 as determined by a chemotaxis bioassay using human MCF-7 cells is less than 10 ng/ml, corresponding to a specific activity of > 1.0 × 10⁵ IU/mg.
• Molecular Mass: Approximately 12.0 kDa, a single non-glycosylated polypeptide chain containing 106 amino acids, which includes a 40-amino acid trefoil motif containing three conserved intramolecular disulfide bonds.
• Protein length: 106
• AA Sequence: EKPSPCQCSRLSPHNRTNCGFPGIT SDQCFDNGCCFDSSVTGVPWCFHPL PKQESDQCVMEVSDRRNCGYPGISP EECASRKCCFSNFIFEVPWCFFPKS VEDCHY
• Endotoxin: Less than 1 EU/µg of rHuTFF2 as determined by LAL method.
• Purity: >97% by SDS-PAGE and HPLC analysis.
• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 centigrade as supplied. 1 month, 2 to 8 centigrade under sterile conditions after reconstitution. 3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
• Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤-20 centigrade. Further dilutions should be made in appropriate buffered solutions.

Gene Information

• Gene Name: TFF2
• Official Symbol: TFF2
• Synonyms: TFF2; trefoil factor 2; SML1, spasmolytic protein 1; spasmolysin; spasmolytic protein 1; spasmolytic polypeptide; SP; SML1
• Gene ID: 7032
• mRNA Refseq: NM_005423
• Protein Refseq: NP_005414
• MIM: 182590
• UniProt ID: Q03403

Reviews

03/14/2020

The manufacturer's technical support can also aid researchers in the data analysis phase.

12/17/2018

the manufacturer's technical support is instrumental in assisting researchers throughout their trials.

04/15/2016

They can provide valuable guidance in experimental design, optimization, and troubleshooting, helping researchers overcome challenges and maximize the efficiency of their trials.

Q&As

How does TFF2 protein contribute to the protection of the gastric mucosa?

TFF2 promotes the formation of a protective mucous layer on the stomach lining, preventing damage from stomach acid and other harmful factors.

Can TFF2 protein be administered orally for clinical applications?

Researchers are exploring various methods of delivering TFF2 protein, including oral administration, to treat gastrointestinal conditions.

In what ways is TFF2 protein being studied for potential therapeutic applications in IBD?

TFF2 is being investigated for its potential to reduce inflammation and promote mucosal healing in IBD patients.

Are there ongoing clinical trials or research investigating the therapeutic potential of TFF2 protein?

Yes, there are ongoing studies exploring the use of TFF2 protein in the treatment of various gastrointestinal disorders.

How does TFF2 protein compare to other treatments for gastric ulcers or IBD?

TFF2 protein-based therapies may offer an alternative or complementary approach to traditional treatments for these conditions.